1B1.F ONCOARENDI THERAP ZY-01
- Market cap
- EUR 29.2M
- P/E
- -
- P/B
- 1.43x
- ROE
- -21.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2025.
Is 1B1.F undervalued?
Graham numberThe Graham number of ONCOARENDI THERAP ZY-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ONCOARENDI THERAP ZY-01 fundamental analysis
No fundamental analysis for ONCOARENDI THERAP ZY-01 yet.
ONCOARENDI THERAP ZY-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ONCOARENDI THERAP ZY-01
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Pha…
Full company profileONCOARENDI THERAP ZY-01 financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
ONCOARENDI THERAP ZY-01 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 400.00 | 0.00 | 100.00 | 0.00 | 0.00 |
| Gross Profit | -2.77M | -1.63M | -4.10M | -3.41M | -2.75M |
| Operating Income | -13.8M | -17.0M | -32.1M | -32.3M | -22.2M |
| EBITDA | -13.3M | -14.0M | -24.5M | -27.5M | -17.6M |
| Net Income | -13.6M | -15.3M | -28.4M | -31.3M | -20.7M |
| EPS | -0.98 | -1.09 | -1.69 | -1.55 | -1.03 |
| Balance Sheet | |||||
| Total Assets | 152M | 138M | 112M | 114M | 107M |
| Total Liabilities | 10.4M | 11.6M | 11.3M | 10.3M | 9.24M |
| Shareholders' Equity | 141M | 126M | 101M | 103M | 98.2M |
| Cash & Short-term Investments | 102M | 65.6M | 64.0M | 18.2M | 40.7M |
| Cash Flow | |||||
| Operating Cash Flow | -13.5M | -10.2M | -23.3M | -57.0M | - |
| Capital Expenditure | 18.8M | 33.6M | 33.9M | 23.8M | 0.00 |
| Free Cash Flow | -32.3M | -43.8M | -57.2M | -80.8M | - |
| Ratios | |||||
| ROE | -9.7% | -12.1% | -28.1% | -30.3% | -21.1% |
| ROA | -9.0% | -11.1% | -25.3% | -27.5% | -19.3% |
| Net Profit Margin | -3,409,079.8% | - | -28,373,117.0% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ONCOARENDI THERAP ZY-01 dividends
ONCOARENDI THERAP ZY-01 has not paid dividends in the last 5 fiscal years.
Who owns ONCOARENDI THERAP ZY-01
- Insiders 29.29%
- Institutions 9.31%
- Public & others 61.40%
- Shares outstanding 24.7M
- Free float 13.3M
ONCOARENDI THERAP ZY-01 company profile
- Company name
- ONCOARENDI THERAP ZY-01
- Ticker
- 1B1.F
- ISIN
- PLONCTH00011
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Fiscal year end
- December
- Address
- Zwirki i Wigury 101, Warsaw, Poland, 02-089
- Phone
- 48 225 52 67 24
- Website
- molecure.com
About ONCOARENDI THERAP ZY-01
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
ONCOARENDI THERAP ZY-01 management
8- Dr. Marcin Jan Szumowski Ph.D.Co-Founder, CEO & President of Management Board
- Dr. Zbigniew ZaslonaChief Scientific Officer & Member of Management Board
- Ms. Agnieszka Rajczuk-SzczepanskaHR Director
- Dr. Adam Golebiowski Ph.D.Co-Founder & VP of Research Chemistry
- Mr. Jacek Olczak Ph.D.Co-Founder & Head of Medicinal Chemistry
- Ms. Monika CzarneckaFinance Director
- Ms. Magdalena TyszkiewiczHead of CMC
- Mr. Dariusz Stencel M.D., Ph.D.Chief Medical Officer